



National Cancer Control Programme

Margaret Triggs
Chief II Pharmacist
NCCP Cancer Drug Management Programme
Contact E-mail: oncologydrugs@cancercontrol.ie





NCCP Systemic Therapy Programme

- Cancer Strategy
- Regimen development
- Guidance documents, e.g.
 - Oncology Medication Safety Review Report 2014
 - OAM Model of Care Recommendations 2018
 - SACT Model of Care 2022
- NCCP Technology Review Committee
- Workforce planning / Service planning
- Education
- Molecular diagnostics
- National Cancer Information System (NCIS)

SACT Guidance, Documents and Resources

SACT Guidance, Documents and Resources

Please click on the links below to access NCCP guidance, documents and resources

Guidance Documents

[NCCP Systemic Anti-Cancer Model of Care](#)

[NCCP Guidance on the use of Biosimilars in Cancer Treatment](#)

[NCCP Guidance on the Provision of Parenteral SACT and Supportive Care in the Community](#)

[NCCP Guidance on bevacizumab Rapid Infusion Rate](#)

[NCCP Guidance on rTUXImab Rapid Infusion Rate](#)

[NCCP Oncology Medication Safety Review](#)

[Oral Anti-Cancer Medicines Model of Care \(Rec 80\)](#)

[Minimum Personnel for Day Wards \(Rec 16\)](#)

[Consent Form for SACT \(National Template\) \(Rec 37\)](#)

[Guidance on the Built Environment of a Haematology/ Oncology Day Ward \(Rec 9\)](#)

[NCCP Guidance on Intrathecal Chemotherapy](#)

[NCCP Guidance on Neurotoxins \(including Vinca Alkaloids\)](#)

[NCCP Guidance on Dose Banding for SACT](#)

[NCCP Guidance: Making Best Use of SACT Aseptic Compounding Capacity](#)

[NCCP Guidance Document for Off Site Transportation of Products from Hospital Pharmacy](#)

[NCCP Guidance: Pharmacy Benchmark preparation of monoclonal antibodies \(mAbs\) used in the treatment of cancer](#)


[NCCP Guidance for Medical Radioisotopes Facilities and Services in the event of Brexit](#)

[NCCP Guidance: Patient selection for the use of immunoglobulin replacement therapy in cancer patients with secondary immunodeficiency](#)

[NCCP Guidance on Management - challenges in medical oncology - haematology day units.pdf \(size: 679.1 KB\)](#)

Documents


[NCCP Position Paper on the use of Tall Man Lettering](#)





NCCP National SACT Regimens

- Key enabler of safe & quality treatment of patients with SACT
- Support safe, evidence based treatment
- Standardised national approach
 - Don't direct care
 - Standard template
- >480 regimens
 - Includes **oral anti-cancer medicines**
- Robust Development/ Approval Process
 - Lead clinician and HCPs
- Available on NCCP website



Community Pharmacy Resources

Role of the Pharmacist in supporting patients

- Hospital and Community
- Across cancer continuum
- NCCP resource page on website

NCCP Chemotherapy Regimen

Carfilzomib (27mg/m² twice weekly), Lenalidomide and Dexamethasone (KRd) Therapy - 28 day

INDICATIONS FOR USE:

INDICATION
Carfilzomib, lenalidomide and dexamethasone therapy is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

Regimen Code	Reimbursement Status
C30 00405a	ODMS 03/05/2018

TREATMENT:
The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Table 1: Carfilzomib in combination with lenalidomide and dexamethasone*

DRUG	CYCLE 1											
	Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	20	20	3-7	27	27	10-14	15	16	17-21			23-28
Dex (mg)	40			40			40			40		
Lenalidomide [†]				25mg daily								Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21	Week 3 Day 22	Week 3 Day 23	Week 3 Days 24-28
Carfilzomib (mg/m ²)	27	27	3-7	27	27	10-14	15	16	17-21		
Dex (mg)	40			40			40			40	
Lenalidomide [†]				25mg daily							Rest

DRUG

Week 1 Day 1	Week 1 Day 2	Week 1 Days 3-7	Week 2 Day 8	Week 2 Day 9	Week 2 Days 10-14	Week 2 Day 15	Week 2 Day 16	Week 2 Days 17-21
-----------------	-----------------	--------------------	-----------------	-----------------	----------------------	------------------	------------------	----------------------



Pharmacists – significant public influence

- Ipsos MRBI Survey 2023:
 - Most trusted healthcare professional group
 - 96% level of trust
- IPU Pharmacy Usage and Attitudes Survey 2023:
 - 39% see their pharmacist as most important healthcare professional
 - Patients attend pharmacies more frequently than the GP
- WHO systematic review:
 - Community health workers have *a high potential to represent a cost-effective approach to the delivery of primary care services in a variety of contexts*

Community pharmacists in cancer care – evolving role

- **Significant role** in supporting the public to:
 - Reduce their cancer risk
 - Act on potential signs / symptoms of cancer
 - Support patients receiving treatment for their cancer
 - Support patients living with and beyond cancer
- **Role has evolved**, due to increased use of:
 - Systemic anti-cancer therapy (SACT) – due to ↑ in treatment options and incidence / prevalence
 - Supportive therapy for management of side effects and co-morbidities
 - Oral anti-cancer medicines (OAM)
- Research has shown that community pharmacists would welcome increased educational support
 - ✓ Proposal to support them by providing a **Cancer Care Champion Pharmacist Resource**



IOP / NCCP Cancer Care Champion Pharmacist Resource Programme

- A **cancer education resource** for pharmacists to enable them to enhance the care they provide to the general public and to their patients with cancer
 - Focus is on community pharmacists but open to all pharmacists
- Supports a number of the recommendations of: NCCP Oncology Medication Safety Review 2014, NCCP OAM Model of Care 2018, National Cancer Strategy 2017-2026, NCCP Systemic Anti-Cancer Therapy (SACT) Model of Care 2022, Slaintecare